Aurélien Marabelle
YOU?
Author Swipe
View article: Supplementary Figure S7 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S7 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
InterpretML Overall Importance using Explainable Boosting Machines (EBM). The mean absolute score reflects the overall importance assigned by the model to predict each patient's category. All features appear important, with the number of o…
View article: Supplementary Figure S8 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S8 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
Effect of the removal of each criterion on the accuracy of a multinomial logistic regression fit to predict the category of each patient. The minimal losses are underlined, and the maximum are written in bold.
View article: Supplementary Figure S6 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S6 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
InterpretML Overall Importance using Explainable Boosting Machines (EBM). The mean absolute score reflects the overall importance assigned by the model to predict each patient's category. All features appear important, with the number of o…
View article: Supplementary Figure S4 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S4 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
Log Hazard ratio (HR) of each parameter obtained from a cox model fitted to predict survival.
View article: Supplementary Figure S2 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S2 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
Correlation tables of our criteria. Bottom left are spearman coefficients, top right are Phi_K coefficients.
View article: Supplementary Figure S5 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Supplementary Figure S5 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy Open
Radiological feature impact on survival. Radiological features include progression of target lesions > 20%, progression of non-target lesions > 50% and the emergence of new lesions.
View article: 1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial
1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial Open
View article: Phase I (b) study evaluating the safety and efficacy Of intratumoral agonistic anti-CD40 (Selicrelumab) in combination with anti-PD-L1 (Atezolizumab) In patients with refractory or relapsed B cell lymphoma (ITSELF trial)
Phase I (b) study evaluating the safety and efficacy Of intratumoral agonistic anti-CD40 (Selicrelumab) in combination with anti-PD-L1 (Atezolizumab) In patients with refractory or relapsed B cell lymphoma (ITSELF trial) Open
View article: Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade Open
Background The optimal dosing regimen for immune checkpoint blockade (ICB) remains a critical question in oncology. Although immune-related adverse events (irAEs) are common with ICB, the incidence and severity of irAEs following a single …
View article: Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1
Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1 Open
Intravenous anti-CTLA4 with anti-PD1 provides durable tumor responses but generates high rates of severe immune-related adverse events (irAEs) in cancer patients1-3. As opposed to anti-PD1 antibodies, anti-CTLA4 efficacy and toxicity is do…
View article: Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases Open
Background and aims Collagenous colitis is a rare complication of immunotherapy for cancer. We report here 15 cases in order to assess the role of immune checkpoint inhibitors (ICI) in the onset of this disease, describe the histopathologi…
View article: Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers Open
Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mou…
View article: Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors Open
E7766 is a novel stimulator of interferon genes (STING) agonist, capable of potent activation of immune cells and generating strong antitumor response in preclinical murine tumor models. Here we present the safety, efficacy, and biomarker …
View article: Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates Open
Purpose:This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell …
View article: Supplementary Data1 from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Supplementary Data1 from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates Open
supplementary materials
View article: Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma Open
Background Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not al…
View article: Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA
Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA Open
International audience
View article: Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study Open
View article: Acute Kidney Injury in Patients Included in Early-Phase Oncology Clinical Trials, Results of the Akitep Study
Acute Kidney Injury in Patients Included in Early-Phase Oncology Clinical Trials, Results of the Akitep Study Open
View article: Feasibility and clinical relevance of the G-CODE in older adults treated in Phase 1 Clinical Trials at Gustave Roussy
Feasibility and clinical relevance of the G-CODE in older adults treated in Phase 1 Clinical Trials at Gustave Roussy Open
View article: 43 Immune biomarkers from phase 1 first-in-human trial treating advanced cancer patients with DK2<sup>10</sup>(EGFR) compared to <i>ex vivo</i> Diakine<sup>TM</sup> response assay
43 Immune biomarkers from phase 1 first-in-human trial treating advanced cancer patients with DK2<sup>10</sup>(EGFR) compared to <i>ex vivo</i> Diakine<sup>TM</sup> response assay Open
View article: Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer Open
Introduction Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical benefit from these treatments is often dif…
View article: 1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 Open
View article: 145 Real-time multiomics tumor microenvironment profiling and pan metastatic solid tumor atlas data projection to revolutionize early phase clinical trials
145 Real-time multiomics tumor microenvironment profiling and pan metastatic solid tumor atlas data projection to revolutionize early phase clinical trials Open
View article: Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology Open
Antagonistic monoclonal antibodies (mAbs) targeting inhibitory immune checkpoints have revolutionized the field of oncology. CTLA‐4, PD‐1, and LAG3 are three co‐inhibitory receptors, which can be expressed by subsets of T cells and which p…
View article: 71 Veracyte biopharma spatial proteomic analysis: an enhanced multiplex IHC combined with ISH technology for precision oncology
71 Veracyte biopharma spatial proteomic analysis: an enhanced multiplex IHC combined with ISH technology for precision oncology Open
View article: Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates Open
Purpose: This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell…
View article: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development Open
View article: Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer Open
Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.
View article: CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials Open